Gilead Sciences stock rises 1.18% to $129.26, outperforming market peers

10 articles · Updated · MarketWatch · Apr 28

The stock snapped a two-day losing streak on Tuesday despite the S&P 500 and Dow Jones both declining.
Gilead closed 17.82% below its 52-week high of $157.29, reached on February 11th, with trading volume at 5.8 million shares.
Competitors showed mixed results, with Johnson & Johnson and Abbott Laboratories rising, while Pfizer fell; Gilead's trading volume remained below its 50-day average.

With 'Strong Buy' ratings, why does Gilead's valuation continue to lag behind its pharmaceutical industry peers?

As the May 7th earnings report nears, will Gilead deliver the positive surprise that investors are hoping for?

Is Gilead's aggressive push into oncology a brilliant pivot or a high-risk gamble away from its HIV dominance?

Will Gilead's new 'transformative' therapies be affordable, or will they repeat past pricing controversies?

How is Gilead using AI to achieve its ambitious goal of launching 10 new transformative therapies by 2030?